Enanta Pharmaceuticals Announces Passing of Chief Financial and Administrative Officer Paul J. Mellett Jr.

Enanta Pharmaceuticals has announced the passing of its longtime Chief Financial and Administrative Officer, Paul J. Mellett Jr. The company's CEO, Jay R. Luly, praised Mellett for his leadership, generosity, and dedication to the company. Mellett joined Enanta in 2003 and played a key role in the company's growth and success, including the development of medications for chronic hepatitis C virus infection. He will be remembered for his humility, compassion, and authentic relationships with colleagues.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has announced the passing of its longtime Chief Financial and Administrative Officer, Paul J. Mellett Jr. The company's CEO, Jay R. Luly, praised Mellett for his leadership, generosity, and dedication to the company. Mellett joined Enanta in 2003 and played a key role in the company's growth and success, including the development of medications for chronic hepatitis C virus infection. He will be remembered for his humility, compassion, and authentic relationships with colleagues [1].

Mellett's career spanned nearly 50 years, with notable positions at Essential Therapeutics, GelTex Pharmaceuticals, and Marshall Contractors. He was also a board member of Norwood Hospital and Big Brothers Big Sisters of Boston, demonstrating his commitment to service. His legacy at Enanta includes establishing the finance department, leading the company's initial public offering in 2013, and advancing strategic partnerships, such as the collaboration with Abbott (now AbbVie) that resulted in the commercialization of VIEKIRA PAK® and MAVYRET®/MAVIRET®, which have cured more than one million patients globally [1].

In light of Mellett's passing, Harry R. Trout, III, and Kathleen S. Capps, CPA, have been appointed as the Company’s principal financial officer and principal accounting officer, respectively, on an interim basis [1].

References:
[1] https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-announces-the-passing-of-its-beloved-and-dlzke19fs1w5.html